EyePoint, Inc. EYPT
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
1/9
Piotroski F — financial health
-3.58
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $31.4M | -$232.0M | — | -$243.4M | $306.1M |
| 2024 | $43.3M | -$130.9M | — | -$130.3M | $336.5M |
| 2023 | $46.0M | -$70.8M | — | -$1.6M | $266.3M |
| 2022 | $41.4M | -$102.3M | — | -$67.2M | $96.4M |
| 2021 | $36.9M | -$58.4M | — | -$50.3M | $184.4M |
| 2020 | $34.4M | -$45.4M | — | -$14.8M | $18.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Elston George | Chief Financial Officer | 2026-05-25 | Tax withheld | 3,627 | $12.93 |
| Elston George | Chief Financial Officer | 2026-05-25 | Option exercise | 7,500 | — |
| Ribeiro Ramiro | Chief Medical Officer | 2026-04-17 | Option exercise | 2,437 | $8.26 |
| Ribeiro Ramiro | Chief Medical Officer | 2026-04-17 | Sell | 2,437 | $15.00 |
| Duker Jay S. | President and CEO | 2026-03-23 | J | 76,766 | $13.11 |
| Duker Jay S. | President and CEO | 2026-03-23 | J | 76,766 | $13.11 |
| Duker Jay S. | President and CEO | 2026-03-16 | Buy | 1,500 | $13.15 |
| Ribeiro Ramiro | Chief Medical Officer | 2026-03-04 | Option exercise | 2,438 | $8.26 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -3.58 (distress)
- Working capital / assets 0.801
- Retained earnings / assets -3.036
- EBIT / assets -0.669
- Equity / liabilities 5.288
Source: SEC EDGAR filings · CIK 0001314102 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.